This week, the FDA decided to pause the Johnson & Johnson vaccine following reports that six women—of the nearly 7 million Americans who have received the J&J vaccine—developed serious blood clots after getting the jab. Is pausing the vaccine worth the tradeoffs? Will the FDA’s move fuel vaccine hesitancy?
Want to see more of The Dispatch in Google search?
Add Us as a Preferred Source



